Replies to post #1466 on NightHawk Biosciences Inc (NHWK)

[Titan V]

It's the same platform (ImPACT), with a different drug.
Bladder -> HS-410 -> vesigenurtacel-L
Lung -> HS-110 -> viagenpumatucel-L

I do not know how different these are scientifically but what I can guess is the Dec 6 data will very likely be unable to have any impact on share price as it's a tiny 8 person p1 trial. Why else did they raise cash today and not after data if the prospects were otherwise?

I see them rebooting the company with their ComPACT platform and redoing the trials from IND for HS-120. Continuing on ImPACT knowing its inferior to ComPACT would be a waste of time and resources, IMO.